Invest in the future of tissue transplantation
VERIGRAFT is the frontrunner in its global market niche: transplanted personalized tissue, not rejected by the human immune system. In fact, VERIGRAFT is creating this global market niche, right now. Investors have the opportunity to secure an early position in a pioneering company, leading a market that is expected to grow considerably during the next 5-10 years.
Fundraising is ongoing, please contact us for details!
Learn more below.
The investment case in brief
Strong business model and experienced leadership
VERIGRAFT develops products based on its proprietary technology. A unique business model allows the company to target severe diseases on a global market. The company is led by an experienced team of entrepreneurs with a combination of commercial and scientific acumen.
Solid patent family and IP-protection
VERIGRAFTs unique technology is protected by world-wide patent families and trade secrets, giving the company a strong competitive advantage in the emerging field of regenerative medicine. The currently granted patents provide protection beyond 2039, and additional patent applications are pending.
The patents cover the technology used to make personalized grafts, the composition of grafts and the application of the grafts for treatment and related activities.
Lead product in clinical development
VERIGRAFT’s P-TEVTM has completed preclinical development and received regulatory and ethical approval for clinicical trials.
Clinical development is ongoing in Europe and has reached important safety assessment milestones.
Targeting globally prevalent, previously untreatable diseases
More than a million CVI patients in Europe and the US could be treated with P-TEVTM
Severe CVI affects millions of people globally every year. For the affected patient and the patient’s family it means drastically reduced quality of life and hardship. For society, the direct and indirect costs associated with CVI amount to billions US$ every year. The need for a solution is highly sought after.
VERIGRAFT’s lead product, P-TEVTM, is currently in clinical development. Preliminary results are positive.
Graph source: Company and other information
Addressing the US$ 3,0B arterial grafts market
According to the Texas Heart Institute, bypass surgery is the most common type of heart surgery with more than 200,000 procedures performed each year in the United States alone. The cost for CABG (coronary artery bypass graft) surgery is very high in western countries. In the US, the average cost of this is around $40,000. Other large indications for vascular grafts are hemodialysis access and peripheral arterial disease.
VERIGRAFT’s P-TEATM grafts can offer a fully biological solution to all indications above, including CABG. The graft will become an integral part of the patient’s body with less complications and lower long-term costs than prosthetic grafts. VERIGRAFT has the potential to become a major actor on the market for arterial grafts. A market that according to the Vascular Grafts Global Market Report 2023, amounts to US$ 2,96B in 2022, and is expected to grow to US$ 4,1B in 2026 at a CAGR of 8,5%.
Graph source: Vascular Grafts Global Market Report 2023
Addressing the US$ 1,3B peripheral nerve grafts market
Peripheral nerve injury significantly affects the quality of life. The peripheral nerve injuries market size is valued at around US$ 1.4 billion in 2021 and it expected to grow (CAGR) 7,65% from 2022 to 2030. The growth forecast is based on the increasing aging population as well as a rising incidence rate of nerve injuries. There is no treatment available today that allows recovery larger distance nerve defects and proximal injuries in long limbs. In these scenarios VERIGRAFT’s P-TENTM grafts offer a potential solution to bridge defects to allow successful reinnervation.
Graph source: Grand View Research
Addressing the US$ 6,9B prosthetic heart valves market
According to the American College of Cardiology, approximately 5 million Americans are diagnosed with heart valve disease annually. High cost of prosthetic heart valves and low availability of alternative options for treatment of heart valve disease are some of the major factors limiting the growth of the market. Currently, according to Allied Market Research, the market amounts to US$ 6,9B in 2021 and is projected to reach 19,7B by 2031, growing at a CAGR of 11,1% from 2022 to 2031.
VERIGRAFT sees great opportunities in developing this market further. The company plans to use its personalization technology to generate fully biological heart valves for implantation. These could provide a novel cure, especially for younger patients and children.
Graph source: Allied Market Research 2023
Why invest?
There is an enormous unmet clinical need for replacement tissues.
Why invest?
Big players have established a large market, yet they’re not offering the benefits of personalization.
Why invest?
Few competitors can offer these new generation products now, but they are working on it.
Why invest?
Preliminary results from our current clinical trial are positive.
Why invest?
VERIGRAFT develops a new generation of products. Today!
Pipeline
VERIGRAFT’s revolutionary technology for personalized tissue has the potential to treat a wide range of indications. The development phase for the product candidates Personalized Tissue-Engineered Veins (P-TEVTM), Personalized Tissue-Engineered Arteries (P-TEATM), Personalized Tissue-Engineered Nerves (P-TENTM) and Personalized Tissue-Engineered Heart Valves (P-TEHVTM) currently range from pre-clinical to clinical development.
Product development for regenerative medicine
Indication
Pre-clinical
Phase I
Phase II
Projects and presentations
Presentations
Scientific publications